Loading…
Reported covered position: Staff, Rep. Barton
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ADVENTIST HEALTHCARE via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy related to copayments and large deductibles; Surprise billing; Advocacy for appropriation funding related to hospital construction efforts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SENIOR CARE PHARMACY COALITION via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Source: Senate LDA
| MR. SETH RABINOWITZ |
| 1 |
| 2019 |
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Advocacy for PAID Act, H.R. 1375 and other Medicare Secondary Payer issues
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Part D coverage of long term care pharmacy and definition of long term care pharmacy
Filing targets: Centers For Medicare and Medicaid Services (CMS), SENATE
MULTICARE HEALTH SYSTEM via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy on hospital issues including trauma center designation issues, surprise billing
MARC COALITION via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMARIN PHARMA, INC. via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy related to cardiovascular health and reduction of residual risk after statins
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
SENIOR CARE PHARMACY COALITION via KING & SPALDING LLP
2019 · third_quarter · Q3
Part D coverage of long term care pharmacy and definition of long term care pharmacy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), SENATE
MULTICARE HEALTH SYSTEM via KING & SPALDING LLP
2019 · third_quarter · Q3
Advocacy on hospital issues including trauma center designation issues, surprise billing
MARC COALITION via KING & SPALDING LLP
2019 · third_quarter · Q3
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMARIN PHARMA, INC. via KING & SPALDING LLP
2019 · third_quarter · Q3
Advocacy related to cardiovascular health and reduction of residual risk after statins
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ADVENTIST HEALTHCARE via KING & SPALDING LLP
2019 · third_quarter · Q3
Advocacy related to copayments and large deductibles; surprise billing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARC COALITION via KING & SPALDING LLP
2019 · second_quarter · 2A
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Treasury, Dept of
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · second_quarter · 2A
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMARIN PHARMA, INC. via KING & SPALDING LLP
2019 · second_quarter · 2A
Advocacy related to cardiovascular health and reduction of residual risk after statins
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
SENIOR CARE PHARMACY COALITION via KING & SPALDING LLP
2019 · second_quarter · Q2
Part D coverage of long term care pharmacy and definition of long term care pharmacy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), SENATE
MULTICARE HEALTH SYSTEM via KING & SPALDING LLP
2019 · second_quarter · Q2
Advocacy on hospital issues including trauma center designation issues, surprise billing
MARC COALITION via KING & SPALDING LLP
2019 · second_quarter · Q2
Advocacy for PAID Act, H.R. 1375, S. 1918 and other Medicare Secondary Payer issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Treasury, Dept of
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMARIN PHARMA, INC. via KING & SPALDING LLP
2019 · second_quarter · Q2
Advocacy related to cardiovascular health and reduction of residual risk after statins
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ADVENTIST HEALTHCARE via KING & SPALDING LLP
2019 · second_quarter · Q2
Advocacy related to copayments and large deductibles; surprise billing
Filing targets: Substance Abuse & Mental Health Services Administration (SAMHSA)
MR. SETH RABINOWITZ via KING & SPALDING LLP
2019 · third_quarter · RR
Medicare-related issues associated with telemedicine services
MULTICARE HEALTH SYSTEM via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy on hospital issues including trauma center designation issues
MARC COALITION via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy for PAID Act, H.R. 1375 and other Medicare Secondary Payer issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Treasury, Dept of
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMARIN PHARMA, INC. via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy related to cardiovascular health and reduction of residual risk after statins
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ADVENTIST HEALTHCARE via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy related to copayments and large deductibles; advocacy related to mental health grant programs
Filing targets: Substance Abuse & Mental Health Services Administration (SAMHSA)